BAYER AG
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
A Study to Learn More About How Safe Dienogest is and How Well it Works Under Real World Conditions in Indian Women With Endometriosis
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2021-03-22
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Bayer
- Target Recruit Count
- 160
- Registration Number
- NCT04808843
- Locations
- 🇮🇳
Many Locations, Multiple Locations, India
A Trial to Learn How BAY1817080 Moves Into, Through and Out of the Body and How Safe it is in Healthy Chinese Men
- First Posted Date
- 2021-03-17
- Last Posted Date
- 2022-10-19
- Lead Sponsor
- Bayer
- Target Recruit Count
- 39
- Registration Number
- NCT04802343
- Locations
- 🇨🇳
Zhongshan Hospital, Fudan University, Shanghai, China
A Study That Uses Data From Routine Eye Examinations of Patients Participating in Studies FIDELIO-DKD and FIGARO-DKD to Explore Whether Finerenone Can Delay the Progression of a Diabetes Complication That Affects the Eyes (Diabetic Retinopathy, DR)
Not Applicable
Completed
- Conditions
- Interventions
- First Posted Date
- 2021-03-12
- Last Posted Date
- 2022-11-02
- Lead Sponsor
- Bayer
- Target Recruit Count
- 70
- Registration Number
- NCT04795726
- Locations
- 🇧🇬
MHAT Sveta Karidad, Plovdiv, Bulgaria
🇧🇬MHAT Hadzhi Dimitar, Sliven, Bulgaria
🇧🇬MHAT Dr. Bratan Shukerov AD, Smolyan, Bulgaria
The Aim of This Study is to Estimate the Discontinuation Rate of Low-dose Levonorgestrel-releasing Intrauterine System Due to Self-reported Unacceptable Menstrual Bleeding Pattern in Spanish Women Who Are Using it for the First Time How Intrauterine System for Long Acting Contraception
Completed
- Conditions
- Interventions
- First Posted Date
- 2021-03-08
- Last Posted Date
- 2023-06-15
- Lead Sponsor
- Bayer
- Target Recruit Count
- 316
- Registration Number
- NCT04785950
- Locations
- 🇪🇸
Many locations, Multiple Locations, Spain
Study to Compare How the Body Absorbs, Distributes and Excretes the Drug Selitrectinib (BAY2731954) Given as Two Different Tablet Formulations or as Liquid Formulations Including the Effect of Food on the Absorption, Distribution or Excretion of the Different Formulations in Healthy Participants
- First Posted Date
- 2021-02-25
- Last Posted Date
- 2021-08-25
- Lead Sponsor
- Bayer
- Target Recruit Count
- 52
- Registration Number
- NCT04771390
- Locations
- 🇺🇸
PAREXEL International, Baltimore, Baltimore, Maryland, United States
🇺🇸Parexel International - Los Angeles, Glendale, California, United States
Darolutamide in Addition to ADT Versus ADT in Metastatic Hormone-sensitive Prostate Cancer
Phase 3
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2021-02-03
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Bayer
- Target Recruit Count
- 662
- Registration Number
- NCT04736199
- Locations
- 🇺🇦
Kyiv City Hospital #3 - Department of Urology, Kyiv, Ukraine
🇦🇺Nepean Hospital, Kingswood, New South Wales, Australia
🇦🇺Northern Cancer Institute, St Leonards, New South Wales, Australia
A Trial to Learn How Much Rivaroxaban Gets Into the Blood When Taken in Different Forms and How Safe They Are in Healthy Men
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2021-01-27
- Last Posted Date
- 2021-01-27
- Lead Sponsor
- Bayer
- Target Recruit Count
- 30
- Registration Number
- NCT04727021
- Locations
- 🇩🇪
CRS Clinical-Research-Services Mönchengladbach GmbH, Mönchengladbach, Nordrhein-Westfalen, Germany
A Trial to Learn How Safe Vericiguat (BAY1021189) is and the Way the Body Absorbs, Distributes and Gets Rid of Vericiguat in Participants With Liver Disease and in Age-, Weight- and Gender-matched Healthy Participants
- First Posted Date
- 2021-01-25
- Last Posted Date
- 2021-01-25
- Lead Sponsor
- Bayer
- Target Recruit Count
- 27
- Registration Number
- NCT04722562
A Trial to Learn How Safe Vericiguat (BAY1021189) is and the Way the Body Absorbs, Distributes and Gets Rid of Vericiguat in Participants With Kidney Disease and in Age-, Weight- and Gender-matched Healthy Participants
- First Posted Date
- 2021-01-25
- Last Posted Date
- 2021-01-25
- Lead Sponsor
- Bayer
- Target Recruit Count
- 39
- Registration Number
- NCT04722484
A Study to Collect Information on the Characteristics of Elderly Belgian Patients With NVAF That Are Treated With a NOAC for This Indication With a Special Focus on Their Fear of Bleeding While Using a NOAC vs the Clinical Benefit of a NOAC of Thrombosis/Stroke Prevention.
Completed
- Conditions
- Interventions
- First Posted Date
- 2021-01-25
- Last Posted Date
- 2022-03-22
- Lead Sponsor
- Bayer
- Target Recruit Count
- 103
- Registration Number
- NCT04722679
- Locations
- 🇧🇪
Many Locations, Multiple Locations, Belgium
© Copyright 2024. All Rights Reserved by MedPath